Capreomycin and the structurally similar compound viomycin are cyclic peptide antibiotics which are particularly active against Mycobacterium tuberculosis, including multi-drug resistant strains. Both antibiotics bind across the ribosomal interface involving 23S rRNA helix 69 (H69) and 16S rRNA helix 44 (h44). The binding site of tuberactinomycins in h44 partially overlaps with that of aminoglycosides and they share with these drugs the side effect of irreversible hearing loss. Here we studied the drug-target interaction on ribosomes modified by site-directed mutagenesis. We identified rRNA residues in h44 as the main determinants of phylogenetic selectivity, predict compensatory evolution to impact on future resistance development and propose mechanisms involved in tuberactinomycin ototoxicity which may enable the development of improved less toxic derivatives. partially overlaps with that of aminoglycosides and they share with these drugs the side effect 28 of irreversible hearing loss. Here we studied the drug-target interaction on ribosomes 29 modified by site-directed mutagenesis. We identified rRNA residues in h44 as the main 30 determinants of phylogenetic selectivity, predict compensatory evolution to impact on future 31 resistance development and propose mechanisms involved in tuberactinomycin ototoxicity 32 which may enable the development of improved less toxic derivatives. 33
B2a formed by interaction between helix H69 of the 23S rRNA and helix h44 of the 16S 43 rRNA (34) (Fig. 1 A-C) . Inhibition of translocation during peptide elongation is the main 44 mechanism of drug action mediating the compound's antibacterial activity (24, 26) . 45 Mutational alterations of nucleotides in 23S or 16S rRNA affect drug binding (8, 13, 18, 20, 46 3/23 37). In addition, the loss of 2'-O-methylation of C1920 (rRNA nucleotides are numbered 47 according to Escherichia coli throughout the paper) in H69 and of C1409 in h44 by TlyA 48 reduces susceptibility to capreomycin (17, 21). Interestingly, Thermus thermophilus TlyA 49 modifies only C1920 in H69 of 23S rRNA, but not C1409 in h44 of 16S rRNA. Inactivation 50 of tlyA in T. thermophilus does not affect its sensitivity to capreomycin (25), suggesting that 51 modification of C1409 is the relevant determinant of increased drug susceptibility due to 2'-52 O-methylation. 53
Much of the unwanted side effects of ribosomal antibiotics reflect limitations in selectivity (2, 54
3), as has been demonstrated for chloramphenicol and linezolid (23, 38) . Together with the 55 structurally unrelated class of aminoglycoside antibiotics, the tuberactinomycins share 56 ototoxicity (irreversible loss of hearing) as a common and unique side effect (7, 35) . 57
Tuberactinomycins affect bacterial protein synthesis apparently by stabilizing peptidyl-tRNA 58 in the pretranslocation complex preventing translocation of the ribosome along the mRNA 59 (11, 19, 24, 26) . The recent crystal structure of the 70S ribosome from T. thermophilus in 60 complex with viomycin or capreomycin at 3.3 -3.5 Angstrom resolution has delineated 61 important details on drug binding and mechanisms of translocation inhibition (34) (Fig. 1 A-62 C). Based on the structural information available we set out to characterize the drug-target 63 interaction in molecular detail. Specifically, we investigated structure-function relationships 64 by assessing the compounds' determinants of specificity, selectivity and resistance 65 development. 66 
Materials and Methods 67

Isolation and purification of ribosomes 79
Ribosomes were purified from bacterial cell pellets by sucrose gradient (10-40%) 80 centrifugation as described previously (6). Ribosome concentrations of 70S were determined 81 by absorption measurements on the basis of 23 pmol ribosomes per A 260 unit. Integrity and 82 functional activity of purified 70S ribosomes was determined by analytical ultracentrifugation 83 and by assessing their capacity to form initiation complexes (6). 84
Cell-free luciferase translation assays 85
Purified 70S hybrid ribosomes and in-vitro transcribed mRNA were used in translation 86 reactions. Firefly luciferase mRNA was produced using T7 RNA polymerase in-vitro. A 87 typical translation reaction contained 0.25 µM 70S ribosomes, 500 ng mRNA, 40% (vol/vol) 88 of M. smegmatis S100 extract, 200 µM amino acid mixture, 0.3 µL 50 x protease inhibitor 89 cocktail (Roche) and RNasin (40 units; Promega), 0.4 mg/ml of tRNAs, and 6 µL of 90 commercial S30 Premix without Amino Acids (Promega). The total volume of reaction was 91 15 µL. The reaction mixture was incubated at 37°C and stopped on ice. Finally, 100 µL of 92 luciferase assay substrate (Promega) were added and the bioluminescence was measured in a 93 luminometer (Bio-Tek Instruments; FLx800). 94 cognate) into firefly luciferase to replace the functionally important amino acid His245 (CAC 96 codon). As a negative control we introduced the Arg245 non-cognate AGA codon, as 97 ribosomal misreading affects decoding of near-cognate codons but not that of non-cognate 98 codons (30). Firefly (F-luc) and renilla luciferase (R-luc) mRNAs were produced using T7 99 polymerase in-vitro on templates of modified plasmids pGL4.14 (F-luc) and pGL4.75 (R-luc) 100 
Minimal inhibitory concentrations (MIC) and fitness assaysmutants indicated as described previously (15). 119
Drug susceptibility of M. tuberculosis and M. bovis BCG was assessed using the MGIT960 120 instrumentation equipped with the TBeXiST software (Becton-Dickinson) as described (33). 121
The cost of a resistance mutation was determined by direct competition against the isogenic 122 drug-susceptible parental strain as described previously (14, 32). 123 in PDB accession numbers 3KNL, 3KNM (capreomycin) and 3KNH, 3KNI (viomycin) (37). 127
Results
128
Determinants of antibacterial activity and fitness of drug resistance mutations 129
To study the relative contribution of individual drug-nucleotide contacts to antibacterial 130 activity, we assessed minimal inhibitory concentrations (MIC) of recombinant 131
Mycobacterium smegmatis constructed previously (32) with point mutations in the h44 drug 132 binding pocket introduced by site-directed mutagenesis ( Table 1 1409A-1491U (see Fig. 2 ). Restoration of 1409-1491 base pairing in part ameliorated fitness 148 (32) but was still associated with a significant degree of tuberactinomycin resistance (see 149 Table 1 ). Of note, the 1409A-1491U interaction retains a high level of drug resistance similar 150 to that of the 1491U resistance alteration alone, yet the 1409A alteration restores the fitness of 151 the 1491U resistance mutation (cost per generation, cpg 11.7% ± 5.9) to wild-type levels (cpg 152 of 1409A -1491U: 0.1% ± 2.9). 153
Mechanisms involved in selectivity and toxicity 154
The mechanism of action of capreomycin and viomycin involves both ribosomal subunits and 155 thus is unique among the ribosome-targeting antibiotics. To study drug selectivity we used 156 hybrid ribosomes (14, 15) with the bacterial h44 replaced by the corresponding cytosolic 157 homolog, resulting in bacterial ribosomes with a humanized drug binding pocket (cyt 14 in 158 ribosomes with a humanized h44 drug binding pocket were in the same range as those of 164 rabbit reticulocytes (Table 2) . To define the relevant polymorphic residues relevant for 165 part of h44 further shortened by mutagenesis to result in bacterial ribosomes with the human 167 1408G and the human 1491A homolog (cyt 2). Drug susceptibility of cyt 2 ribosomes was 168 comparable to that of cyt 14 ribosomes and rabbit ribosomes (Table 2) . From these results we 169 conclude that the phylogenetic variability within h44, more precisely 16S rRNA residues 170 1408 and 1491, is sufficient to account for the drug's ability to discriminate between bacterial 171 and eukaryotic cytosolic ribosomes. Both capreomycin and viomycin bind to the 70S in a cleft formed between H69 of 23S rRNA 206 and h44 of 16S rRNA (see Fig. 1 ). The macrocycle, capreomycidine ring and the 207 ureidodehydroalanine form numerous hydrogen bonds to the ribose phosphate backbone of 208 A1913, C1914 (both 23S rRNA) and A1493 (16S rRNA); side groups of the macrocycle also 209 form contacts to G1491 or A1408 (both 16S rRNA). Despite the close contacts of the 210 tuberactinomycin antibiotics to the phosphate backbone of 23S rRNA residues A1913 and 211 C1914, the polymorphism within h44 of the 16S rRNA is sufficient to account for drug 212 selectivity, leading us to suggest that H69 in the large ribosomal subunit apparently 213 contributes little towards the drug's ability to discriminate between bacterial and eukaryotic 214 cytosolic ribosomes. This is consistent with the high degree of conservation of H69 with 215 the 1408A→G mutation has a small but significant effect on capreomycin susceptibility 217 (relative resistance 8-fold). This finding is explained by the crystal structure, which suggests 218 two (albeit weak) H-bonds between A1408 and capreomycin, but no direct interaction of 219 residue 1408 with viomycin (see Fig. 1 D-E) . As a result of the A1408G substitution, the 220 direct interaction of residue 1408 with capreomycin would be limited to a single H-bond. several hundred-fold higher activity on bacterial compared to eukaryotic ribosomes (see Table  248 2). In support of a common mechanism in aminoglycoside and tuberactinomycin ototoxicity 249
we find that tuberactinomycins demonstrate key features involved in aminoglycoside 250 ototoxicity: misreading induction in mitohybrid ribosomes and increased susceptibility of 251 mutant mitohybrids with the A1555G and C1494U deafness alleles to drug action. However, 252 the structural determinants of selectivity, i.e. the ability to differentiate between prokaryotic 253 and eukaryotic ribosomes, are notably different. While for the clinically used 6'NH 2 4,6-254 aminoglycosides selectivity to a large extent rests upon 16S rRNA residue 1408 (14, 16), 255 selectivity of tuberactinomycin antibiotics mainly involves 16S rRNA residue 1491. We 256 suggest that the structures available together with the determinants of selectivity identified 257 will enable the creation of new compounds by targeted drug design. The adjacent location of 258 these two different classes of antibiotics should provide a means to combine their selectivity 259 in an additive fashion without decreasing their potency as antibacterial agent, e.g. by 260
chemically linking modified portions of tuberactinomycins and ring I of the 6'NH 2 4,6-261 aminoglycosides. These compounds will be particularly valuable for treatment of 262 tuberculosis, as chemotherapy of tuberculosis requires several months of drug treatment, 263 putting the patients at high risk for ototoxicity. 
